Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC

Phase 3

Recruiting

• Conditions: Non-small Cell Lung Cancer
• Interventions: Drug: Placebo; Drug: Savolitinib

• Registration Number: NCT05009836
• Lead Sponsor: Hutchison Medipharma Limited

Brief Summary

A Phase III Clinical Study on Savolitinib Combined with Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic Non-small Cell Lung Cancer

Detailed Description

A Multicenter, Randomized, Double-blind, Phase III Clinical Study to Evaluate the Efficacy and Safety of Savolitinib Combined with Osimertinib versus Placebo Combined with Osimertinib as the First-line Therapy for Patients with EGFRm+/MET+ Locally Advanced or Metastatic Non-small Cell Lung Cancer

Study Timeline

• Study First Submitted: 2021-07-30
• Study First Submitted QC: 2021-08-16
• Study First Posted: 2021-08-18
• Study Start: 2021-09-06
• Status Verified: 2023-03
• Last Update Submitted: 2023-03-29
• Last Update Posted: 2023-03-30
• Primary Completion: 2024-11-15
• Study Completion: 2025-01-31

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 320

Inclusion Criteria

1. Fully aware of this study and voluntary to sign the informed consent form, and being willing and able to comply with the study procedure;

2. Age ≥ 18

3. In accordance with the Eighth Edition of TNM Staging of Lung Cancer by the International Association for the Study of Lung Cancer and American Joint Committee on Cancer, and patients with histologically or cytologically confirmed unresectable locally advanced (stage ⅢB/ⅢC), metastatic or recurrent (stage IV) NSCLC who are not suitable for radical concurrent chemoradiotherapy;

4. Carrying two common EGFR mutations clearly related with the sensitivity to EGFR-TKI (i.e., exon 19 deletion, and L858R) and c-MET overexpression

5. Having measurable lesions (in accordance with RECIST 1.1 criteria);

6. ECOG Performance Status score 0 or 1, or Karnofsky score ≥80;

7. Survival is expected to exceed 12 weeks;

8. No any previous systematic antitumor therapy for advanced/metastatic disease;

9. adequate bone marrow reserve or organ function

10. Female patients of childbearing potential must agree to use effective contraceptive methods from screening period to 4 weeks after discontinuation of the study drug 11. Male patients whose sexual partners are women of childbearing potential must use condoms during sexual intercourse during the study and within 6 months after discontinuation of study drug

11. Being able to take or swallow the drug orally.

Exclusion Criteria

1. Previous treatment with EGFR inhibitors or MET inhibitors;
2. Currently having other malignant tumors, or having other infiltrating malignant tumors in the past 5 years
3. Antitumor therapy within 2 weeks prior to the start of study treatment, including hormone therapy, biotherapy, immunotherapy or the traditional Chinese medicine for antitumor indication;
4. Having received extensive radiotherapy (including radionuclide therapy, e.g., Sr-89) within 4 weeks prior to the start of study treatment or palliative local radiotherapy within one week prior to the start of study treatment, or the above adverse reactions of radiotherapy did not recover;
5. Having received a major surgery within 4 weeks prior to the start of study treatment or a minor surgery (except biopsy, and venous catheterization) within one week prior to the start of study treatment;
6. Currently receiving the potent CYP3A4 inducers or potent CYP1A2 inhibitors within two weeks prior to the start of study treatment;
7. Having not been sufficiently recovered from the toxicity and/or complication resulting from any interventional measure prior to the start of treatment;
8. Clinically significant active infection, including but not limited to tuberculosis, human immunodeficiency virus (HIV) infection (positive HIV1/2 antibody);
9. Active hepatitis B, or active hepatitis C;
10. Acute myocardial infarction, unstable angina pectoris, stroke or transient ischemic attack;
11. Uncontrollable hypertension despite the use of drugs,
12. Mean resting corrected QT interval (QTcF) or Any important abnormality in rhythm;
13. Patients whose known cancerous thrombus or deep vein thrombosis are stable for ≥2 weeks after receiving treatment with low molecular weight heparin (LMWH) or analogues with similar efficacy can be enrolled;
14. Any important abnormality in rhythm
15. Presence of meningeal metastasis, spinal cord compression or active brain metastasis prior to the start of study treatment.
16. Known allergy to the active or inactive ingredient of Savolitinib or Osimertinib;
17. Lack of compliance with participation in this clinical study or inability to comply with the limitations and requirements of the study, as judged by investigators;
18. Having participated in other drug clinical trials and received the study drug within 3 weeks prior to the start of study treatment; 19. Known allergy to the active or inactive ingredient of Savolitinib or Osimertinib; 20. Previous history of interstitial lung diseases, drug-induced interstitial lung diseases, radiation pneumonitis requiring glucocorticoid therapy and any active interstitial lung diseases; 21. Pregnant and lactating women; 22. Any other disease, metabolic abnormality, physical examination abnormality or laboratory examination abnormality, certain disease or state, based on which there is a reason to suspect that the subject is not suitable for the study drug, or one condition that will affect intepretaton of the study results or put the subject at high risk.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
placebo	Placebo	placebo 600 mg or 400 mg QD orally+ Osimertinib 80 mg QD orally ( every 3 weeks)
Savolitinib	Savolitinib	Savolitinib 600 mg or 400 mg QD orally +Osimertinib 80 mg QD orally ( every 3 weeks)

Primary Outcome Measures

Name	Time	Method
PFS	17 months after the last patient enrolled	Progression-free survival (PFS) using Investigator assessment as defined by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1)

Secondary Outcome Measures

Name	Time	Method
Safety and tolerability	17 months after the last patient enrolled	Incidence and nature of treatment emergent adverse events (TEAE), the other safety variables including physical examination, vital signs and laboratory examinations
The objective response rate of the tumor (ORR)	17 months after the last patient enrolled	the incidence of confirmed complete response or partial response
The disease control rate (DCR)	17 months after the last patient enrolled	the incidence of complete response, partial response and stable disease
Duration of Response (DoR)	17 months after the last patient enrolled	the duration between the date the criteria for complete response or partial response was first measured (first record shall prevail) and the date of disease recurrence or progression as objectively recorded
Overall survival (OS)	17 months after the last patient enrolled	the time from the date of randomization to the date of death (all causes)
Time to Response (TTR)	17 months after the last patient enrolled	the period from the date of randomization to the date when the criteria for complete response or partial response was first measured (first record shall prevail).
PFS	17 months after the last patient enrolled	Progression-free survival (PFS) using IRC as defined by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1)
Development of diagnostic technology	17 months after the last patient enrolled	The residual samples may be used for development of MET Companion Diagnostics (CDx)

Trial Locations

Locations (1)

Guangdong General Hospital; 🇨🇳 Guangzhou, China